Published in J Biol Chem on October 01, 2008
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood (2011) 1.86
A molecular perspective on TH2-promoting cytokine receptors in patients with allergic disease. J Allergy Clin Immunol (2013) 1.73
Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem (2009) 1.07
Structural reorganization of the interleukin-7 signaling complex. Proc Natl Acad Sci U S A (2012) 1.06
Structural insights into the common γ-chain family of cytokines and receptors from the interleukin-7 pathway. Immunol Rev (2012) 0.91
Discovery and initial characterization of Th9 cells: the early years. Semin Immunopathol (2016) 0.86
Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities. J Biol Chem (2015) 0.82
Eliminative signaling by Janus kinases: role in the downregulation of associated receptors. J Cell Biochem (2014) 0.76
IL-7 Induces an Epitope Masking of γc Protein in IL-7 Receptor Signaling Complex. Mediators Inflamm (2017) 0.75
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 26.02
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Cell signaling by receptor tyrosine kinases. Cell (2000) 18.16
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature (1982) 9.42
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity (1995) 6.91
Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell (1985) 6.06
Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature (1991) 5.51
Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science (1995) 5.27
Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med (1987) 4.53
Cloning of the gamma chain of the human IL-2 receptor. Science (1992) 4.50
Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science (1986) 4.30
The Stat family in cytokine signaling. Curr Opin Cell Biol (2001) 4.10
The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med (1987) 3.66
Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity (1999) 3.53
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science (1999) 3.03
Erythropoietin receptor activation by a ligand-induced conformation change. Science (1999) 2.98
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell (2006) 2.69
Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science (2005) 2.64
Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol Biol Cell (2000) 2.08
Biology of the interleukin-2 receptor. Adv Immunol (1998) 2.08
Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A (2001) 2.00
Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature (1994) 1.93
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell (2003) 1.84
Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol (2005) 1.83
Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature (1994) 1.83
Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal Biochem (2000) 1.79
The types II and III transforming growth factor-beta receptors form homo-oligomers. J Cell Biol (1994) 1.76
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem (2005) 1.74
Co-localization analysis of complex formation among membrane proteins by computerized fluorescence microscopy: application to immunofluorescence co-patching studies. J Microsc (2003) 1.72
Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Immunol Rev (1995) 1.61
Oligomeric structure of type I and type II transforming growth factor beta receptors: homodimers form in the ER and persist at the plasma membrane. J Cell Biol (1998) 1.56
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem (2007) 1.55
Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol (1996) 1.53
IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol (2007) 1.44
IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors (2004) 1.43
Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem (2005) 1.41
Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A (2006) 1.41
Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity (1999) 1.40
Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex. Int Immunol (1995) 1.39
Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr Biol (2001) 1.19
Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: a fluorescence resonance energy transfer study. Proc Natl Acad Sci U S A (1997) 1.17
Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood (1999) 1.07
Mapping of binding site III in the leptin receptor and modeling of a hexameric leptin.leptin receptor complex. J Biol Chem (2006) 1.03
The murine interleukin-2 receptor gamma chain gene: organization, chromosomal localization and expression in the adult thymus. Eur J Immunol (1994) 1.02
Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited. Mol Cell Biol (2004) 1.01
Cloning and expression of a cDNA for the human homolog of mouse T cell and mast cell growth factor P40. Cytokine (1990) 0.97
Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain. EMBO J (1999) 0.95
The erythropoietin receptor transmembrane domain mediates complex formation with viral anemic and polycythemic gp55 proteins. J Biol Chem (2003) 0.91
Signalling by cytokines interacting with the interleukin-2 receptor gamma chain. Cytokines Cell Mol Ther (1998) 0.86
Activation of the Jak/Stat signal transduction pathway in GH-treated rat osteoblast-like cells in culture. Mol Cell Endocrinol (2000) 0.86
Internalization-competent influenza hemagglutinin mutants form complexes with clathrin-deficient multivalent AP-2 oligomers in live cells. J Biol Chem (2001) 0.86
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature (2008) 10.15
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A (2009) 3.31
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem (2002) 2.73
Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells. J Cell Biol (2002) 2.62
NetPath: a public resource of curated signal transduction pathways. Genome Biol (2010) 2.62
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood (2013) 2.60
IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol (2007) 2.60
The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem (2001) 2.59
Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem (2004) 2.55
New mutations and pathogenesis of myeloproliferative neoplasms. Blood (2011) 2.53
Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog (2008) 2.38
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol (2008) 2.37
IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol (2002) 2.32
Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling. Mol Cell Biol (2005) 2.24
Differently anchored influenza hemagglutinin mutants display distinct interaction dynamics with mutual rafts. J Cell Biol (2003) 2.22
Three separable domains regulate GTP-dependent association of H-ras with the plasma membrane. Mol Cell Biol (2004) 2.09
Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling. Mol Cell Biol (2006) 1.99
IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol (2011) 1.92
Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry (2006) 1.88
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood (2014) 1.87
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell (2003) 1.84
Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med (2011) 1.78
IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med (2013) 1.75
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem (2005) 1.74
Characterization of the murine alpha interferon gene family. J Virol (2004) 1.72
Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum (2009) 1.70
Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit. Biochem J (2003) 1.61
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood (2012) 1.59
An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med (2009) 1.58
Actomyosin-generated tension controls the molecular kinetics of focal adhesions. J Cell Sci (2011) 1.57
Activating mutations in human acute megakaryoblastic leukemia. Blood (2008) 1.56
Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem (2008) 1.54
Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res (2003) 1.53
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood (2005) 1.50
Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol (2007) 1.50
A role for the juxtamembrane cytoplasm in the molecular dynamics of focal adhesions. PLoS One (2009) 1.50
IL-9 promotes IL-13-dependent paneth cell hyperplasia and up-regulation of innate immunity mediators in intestinal mucosa. J Immunol (2009) 1.48
Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Nucleic Acids Res (2010) 1.47
IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol (2007) 1.44
The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. J Immunol (2009) 1.44
A feedback loop between the liver-enriched transcription factor network and miR-122 controls hepatocyte differentiation. Gastroenterology (2011) 1.44
IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors (2004) 1.43
TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa. J Immunol (2010) 1.43
Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem (2005) 1.41
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood (2010) 1.41
The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem (2004) 1.38
Dual Role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am J Respir Crit Care Med (2011) 1.38
A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis. Proc Natl Acad Sci U S A (2009) 1.30
Transforming growth factor-beta receptors interact with AP2 by direct binding to beta2 subunit. Mol Biol Cell (2002) 1.29
The heel and toe of the cell's foot: a multifaceted approach for understanding the structure and dynamics of focal adhesions. Cell Motil Cytoskeleton (2009) 1.29
Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol (2006) 1.28
Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J Immunol (2004) 1.28
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood (2007) 1.27
IL-17A-producing gammadelta T and Th17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis. J Immunol (2010) 1.25
Comparison of stable human Treg and Th clones by transcriptional profiling. Eur J Immunol (2009) 1.23
Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Mol Cell Biol (2007) 1.22
Crystal structure of the IL-22/IL-22R1 complex and its implications for the IL-22 signaling mechanism. FEBS Lett (2008) 1.22
The disulphide isomerase DsbC cooperates with the oxidase DsbA in a DsbD-independent manner. Mol Microbiol (2007) 1.21
Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem (2008) 1.20
Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J (2003) 1.20
Rac2 regulation of phospholipase C-beta 2 activity and mode of membrane interactions in intact cells. J Biol Chem (2002) 1.19
Homomeric and heteromeric complexes among TGF-β and BMP receptors and their roles in signaling. Cell Signal (2011) 1.18
Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes. J Bone Joint Surg Am (2003) 1.18
Clustering of raft-associated proteins in the external membrane leaflet modulates internal leaflet H-ras diffusion and signaling. Mol Cell Biol (2006) 1.18
A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol (2010) 1.14
IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease. PLoS One (2011) 1.13
Differential roles for the IL-9/IL-9 receptor alpha-chain pathway in systemic and oral antigen-induced anaphylaxis. J Allergy Clin Immunol (2010) 1.13
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica (2011) 1.12
A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program (2005) 1.11
A profibrotic function of IL-12p40 in experimental pulmonary fibrosis. J Immunol (2002) 1.11
Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood (2009) 1.08
Crystal structure of recombinant human interleukin-22. Structure (2002) 1.08
Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. Mol Cell Biol (2005) 1.08
A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med (2005) 1.08
Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene (2003) 1.07
Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem (2009) 1.07
IL-22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-induced eosinophilic airway inflammation. J Allergy Clin Immunol (2011) 1.06
CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. Eur J Immunol (2003) 1.06
Profibrotic effect of IL-9 overexpression in a model of airway remodeling. Am J Respir Cell Mol Biol (2007) 1.05
Microarray analysis of LIF/Stat3 transcriptional targets in embryonic stem cells. Stem Cells (2005) 1.05
JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS One (2010) 1.04